Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
At close: 05:29PM CEST
| Previous close | 212.30 |
| Open | 213.90 |
| Bid | 212.80 x 0 |
| Ask | 213.10 x 0 |
| Day's range | 209.50 - 214.90 |
| 52-week range | 139.55 - 245.40 |
| Volume | |
| Avg. volume | 607,463 |
| Market cap | 62.927B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 25.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Sobi publishes Q1 2022 report
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2022
- PR Newswire
Sobi publishes 2021 Annual and Sustainability Report
Swedish Orphan Biovitrum AB (publ) (Sobi®) has released the company's 2021 Annual and Sustainability Report. The integrated report summarises business and strategy, financial performance and work on sustainability.
- PR Newswire
Sobi to cease ReFacto manufacturing in the first quarter of 2024
Sobi® today announced that its contract with Pfizer for the manufacture of drug substance for ReFacto AF®/Xyntha® (ReFacto) has been amended due to clarity of final order volumes and will now expire in the first quarter of 2024, earlier than the previous expiry date at the end of 2025. Manufacturing of drug substance for ReFacto will be transferred to Pfizer's production unit in Ireland, ensuring continued patient access.
© 2022 Yahoo. All rights reserved.
